{
    "clinical_study": {
        "@rank": "48609", 
        "arm_group": [
            {
                "arm_group_label": "Lercanidipine 10mg", 
                "arm_group_type": "Active Comparator", 
                "description": "1 Tablet of Zanidip \u00ae 10mg + 1 Tablet of L10/V80 Placebo + 1 Tablet of L10/V160  Placebo (8wks)"
            }, 
            {
                "arm_group_label": "Lercanidipine10mg /Valsartan 80mg", 
                "arm_group_type": "Experimental", 
                "description": "1 Tablet of Zanidip \u00ae 10mg Placebo +1 Tablet of L10/V80 + 1 Tablet of L10/V160 Placebo (8wks)"
            }, 
            {
                "arm_group_label": "Lercanidipine 10mg /Valsartan 160mg", 
                "arm_group_type": "Experimental", 
                "description": "1 Tablet of Zanidip \u00ae 10mg Placebo + 1 Tablet of L10/V80 Placebo + 1 Tablet of L10/ V160 (8wks)"
            }
        ], 
        "brief_summary": {
            "textblock": "This study aims to compare and assess the efficacy and the safety of the combination agent\n      of Lercanidipine and Valsartan and monotherapy of Lercanidipine alone in patients with\n      essential hypertension"
        }, 
        "brief_title": "Phase III Clinical Study to Evaluate the Efficacy and Safety of the Combination of Lercanidipine/Valsartan in Hypertensive Patients", 
        "condition": "Hypertension", 
        "condition_browse": {
            "mesh_term": "Hypertension"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients aged \u2265 20 to \u226475 years old\n\n          -  Patient with essential hypertension\n\n        Exclusion Criteria:\n\n          -  When the BP level measured at screening was sitDBP>120 mmHg or sitSBP >180 mmHg\n\n          -  Patient with difference in repeatedly measured blood pressures from the selected arm\n             at screening was sitSBP\u2265 20mmHg or sitDBP \u2265 10mmHg"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "449", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01928628", 
            "org_study_id": "LG-ZVCL005"
        }, 
        "intervention": [
            {
                "arm_group_label": "Lercanidipine 10mg", 
                "intervention_name": "Lercanidipine 10mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Lercanidipine10mg /Valsartan 80mg", 
                "intervention_name": "Lercanidipine10mg /Valsartan 80mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Lercanidipine 10mg /Valsartan 160mg", 
                "intervention_name": "Lercanidipine 10mg /Valsartan 160mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Lercanidipine10mg /Valsartan 80mg", 
                    "Lercanidipine 10mg /Valsartan 160mg"
                ], 
                "intervention_name": "Lercanidipin 10mg Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Lercanidipine 10mg", 
                    "Lercanidipine 10mg /Valsartan 160mg"
                ], 
                "intervention_name": "Lercanidipine10mg /Valsartan 80mg Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Lercanidipine 10mg", 
                    "Lercanidipine10mg /Valsartan 80mg"
                ], 
                "intervention_name": "Lercanidipine 10mg /Valsartan 160mg Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Valsartan", 
                "Lercanidipine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "August 27, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Seoul National University Hospital"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomized, Multicenter, Parallel Design Phase III Clinical Study to Evaluate the Efficacy and Safety of the Combination of Lercanidipine/Valsartan in Hypertensive Patients Who Are Not Adequately Controlled on Lercanidipine 10mg Monotherapy.", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "South Korea: Korea Food and Drug Administration (KFDA)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Change in mean sitDBP from week 0 to week 40", 
            "safety_issue": "No", 
            "time_frame": "40 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01928628"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Proportion (%) of patients with mean sitDBP<90mmHg or proportion (%) of patients with mean reduction of sitDBP \u226510mmHg from week 0", 
            "measure": "Response rate at week 4 and 8", 
            "safety_issue": "No", 
            "time_frame": "4 weeks and 8 weeks"
        }, 
        "source": "LG Life Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "LG Life Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2012", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}